Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.

Safety and effectiveness of RBD-specific polyclonal equine F(ab´)2 fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study.

Show other versions (1)

<h4>Background</h4>Passive immunotherapy has been evaluated as a therapeutic alternative for patients with COVID-19 disease. Equine polyclonal immunotherapy for COVID-19 (EPIC) showed adequate safety and potential efficacy in a clinical trial setting and obtained emergency use authorizat...

Full description

Bibliographic Details
Main Authors: Diego H Farizano Salazar, Fernando Achinelli, Mariana Colonna, Lucía Pérez, Analía A Giménez, Maria Alejandra Ojeda, Susana N Miranda Puente, Lía Sánchez Negrette, Florencia Cañete, Ornela I Martelotte Ibarra, Santiago Sanguineti, Linus Spatz, Fernando A Goldbaum, Carolina Massa, Marta Rivas, Mariana Pichel, Yanina Hiriart, Vanesa Zylberman, Sandra Gallego, Brenda Konigheim, Francisco Fernández, Matías Deprati, Ian Roubicek, Diego H Giunta, Esteban Nannini, Gustavo Lopardo, Waldo H Belloso, EPIC Study Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0274796

Internet

https://doi.org/10.1371/journal.pone.0274796

Similar Items